Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where David L. Rogers is active.

Publication


Featured researches published by David L. Rogers.


Journal of Aapos | 2011

Prevalence and course of strabismus through age 6 years in participants of the Early Treatment for Retinopathy of Prematurity randomized trial

Deborah K. VanderVeen; Don L. Bremer; Rae R. Fellows; Robert J. Hardy; Daniel E. Neely; Earl A. Palmer; David L. Rogers; Betty Tung; William V. Good

PURPOSE To present strabismus data for children who participated in the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial. METHODS The prevalence of strabismus, categorized as present or absent, was tabulated for all children with history of high-risk prethreshold retinopathy of prematurity (ROP) who participated in the ETROP randomized trial and were examined at 9 months to 6 years of age. Relationships among strabismus and demographic measures, eye characteristics, and neurodevelopmental factors were analyzed. RESULTS Among the 342 children evaluated at 6 years, the prevalence of strabismus was 42.2%. Even with favorable acuity scores in both eyes, the prevalence of strabismus was 25.4%, and with favorable structural outcomes in both eyes the prevalence of strabismus was 34.2%. Of children categorized as visually impaired as the result of either ocular or cerebral causes, 80% were strabismic at the 6-year examination. Of 103 study participants who were strabismic at 9 months, 77 (74.8%) remained so at 6 years. Most strabismus was constant at both the 9-month (62.7%) and the 6-year examination (72.3%). After multiple logistic regression analysis, risk factors for strabismus were abnormal fixation behavior in one or both eyes (P < 0.001), history of amblyopia (P < 0.003), unfavorable structural outcome in one or both eyes (P = 0.025), and history of anisometropia (P = 0.04). Strabismus surgery was performed for 53 children. By 6 years, the cumulative prevalence of strabismus was 59.4%. CONCLUSIONS Most children with a history of high-risk prethreshold ROP develop strabismus at some time during the first 6 years of life.


Pediatrics | 2013

Patterns of Retinal Hemorrhage Associated With Increased Intracranial Pressure in Children

Gil Binenbaum; David L. Rogers; Brian J. Forbes; Alex V. Levin; Sireesha A. Clark; Cindy W. Christian; Grant T. Liu; Robert A. Avery

OBJECTIVE: Raised intracranial pressure (ICP) has been proposed as an isolated cause of retinal hemorrhages (RHs) in children with suspected traumatic head injury. We examined the incidence and patterns of RHs associated with increased ICP in children without trauma, measured by lumbar puncture (LP). METHODS: Children undergoing LP as part of their routine clinical care were studied prospectively at the Childrens Hospital of Philadelphia and retrospectively at Nationwide Children’s Hospital. Inclusion criteria were absence of trauma, LP opening pressure (OP) ≥20 cm of water (cm H2O), and a dilated fundus examination by an ophthalmologist or neuro-ophthalmologist. RESULTS: One hundred children were studied (mean age: 12 years; range: 3–17 years). Mean OP was 35 cm H2O (range: 20–56 cm H2O); 68 (68%) children had OP >28 cm H2O. The most frequent etiology was idiopathic intracranial hypertension (70%). Seventy-four children had papilledema. Sixteen children had RH: 8 had superficial intraretinal peripapillary RH adjacent to a swollen optic disc, and 8 had only splinter hemorrhages directly on a swollen disc. All had significantly elevated OP (mean: 42 cm H2O). CONCLUSIONS: Only a small proportion of children with nontraumatic elevated ICP have RHs. When present, RHs are associated with markedly elevated OP, intraretinal, and invariably located adjacent to a swollen optic disc. This peripapillary pattern is distinct from the multilayered, widespread pattern of RH in abusive head trauma. When RHs are numerous, multilayered, or not near a swollen optic disc (eg, elsewhere in the posterior pole or in the retinal periphery), increased ICP alone is unlikely to be the cause.


Journal of Aapos | 2011

Treatment of symptomatic convergence insufficiency with a home-based computer orthoptic exercise program

Angela Serna; David L. Rogers; Mary Lou McGregor; Richard P. Golden; Don L. Bremer; Gary L. Rogers

PURPOSE To determine the efficacy of a home-based computer orthoptic program to treat symptomatic convergence insufficiency. METHODS A retrospective review of consecutive patients with symptomatic convergence insufficiency treated with a home-based computer orthoptic program was performed. Symptomatic convergence insufficiency was defined as: near point of convergence (NPC) >6 cm, decreased positive fusional vergence, exophoria at near at least 4(Δ) greater than at far, and documented complaints of asthenopia, diplopia, or headaches with reading or near work. The Computer Orthoptics CVS program was used for this study. Before beginning the computer orthoptic program, patients with an NPC >50 cm were given 4 base-in prisms and push-up exercises (NPC exercises with an accommodative target) for 2 weeks. RESULTS A total of 42 patients were included. Mean treatment duration was 12.6 weeks; mean follow-up, 8.5 months. Of the 42 patients, 35 were treated with the home-based computer orthoptic program and push-up exercises; the remaining 7 only used the computer orthoptic program. Because of a remote NPC, 5 patients were given base-in Fresnel prism before starting treatment. Baseline mean NPC was 24.2 cm; posttreatment mean NPC improved to 5.6 cm: 39 patients (92.8%) achieved an NPC of ≤6 cm (p < 0.001). Positive fusional vergence improved in 39 patients (92.8%). Fourteen patients reduced their near exophoria by ≥5(Δ). A total of 27 patients (64.2%) reported resolution of symptoms after treatment. CONCLUSIONS In our study, home-based computer orthoptic exercises reduced symptoms and improved NPC and fusional amplitudes. The computer orthoptic program is an effective option for treating symptomatic convergence insufficiency.


Archives of Ophthalmology | 2010

Pilot study of levodopa dose as treatment for residual amblyopia in children aged 8 years to younger than 18 years.

Michael X. Repka; Raymond T. Kraker; Roy W. Beck; C. Scott Atkinson; Darron A. Bacal; Don L. Bremer; Patricia L. Davis; Matthew Gearinger; Stephen R. Glaser; Darren L. Hoover; Daniel M. Laby; David G. Morrison; David L. Rogers; Nicholas A. Sala; Donny W. Suh; Maynard B. Wheeler

P rior studies have evaluated levodopa as an adjunct toocclusiontherapyinthetreatmentofamblyopia. Improvement in visual acuity after completion of a course of levodopa has been reported; however, regression has occurred in several studies after stopping the medication. Reportedadverseeffectsof levodopaweremild.They haveincludednausea,headache,fatigue,moodchanges,emesis,dizziness,drymouth,decreasedappetite,andnightmares. Inpreparationforconductingaphase3randomizedtrial, weconductedaprospective randomizedpilot study toprovide a preliminary assessment of the efficacy and safety of 2 doses of levodopa combined with daily ocular occlusion therapyofthefelloweyeinolderchildrenandteenagerswith residualamblyopiafromstrabismus,anisometropia,orboth.


Pediatric Clinics of North America | 2014

A Review of Pediatric Idiopathic Intracranial Hypertension

David L. Rogers

It is now well recognized that idiopathic intracranial hypertension (IIH) can occur in children. Relative to the adult population, the demographic features and clinical presentation of IIH as well as the diagnosis and treatment guidelines for children are quite different. Although these differences are well established, specific diagnostic and treatment guidelines for pediatric patients have largely been based on the adult literature. Exciting new evidence is now available to assist the clinician in managing pediatric patients with IIH.


JAMA Ophthalmology | 2017

Assessment of lower doses of intravitreous bevacizumab for retinopathy of prematurity a phase 1 dosing study

David K. Wallace; Raymond T. Kraker; Sharon F. Freedman; Eric R. Crouch; Amy K. Hutchinson; Amit R. Bhatt; David L. Rogers; Michael B. Yang; Kathryn M. Haider; Deborah K. Van Der Veen; R. Michael Siatkowski; Trevano W. Dean; Roy W. Beck; Michael X. Repka; Lois E. H. Smith; William V. Good; Mary Elizabeth Hartnett; Lingkun Kong; Jonathan M. Holmes

Importance Intravitreous bevacizumab (0.25 to 0.625 mg) is increasingly used to treat type 1 retinopathy of prematurity (ROP), but there remain concerns about systemic toxicity. A much lower dose may be effective while reducing systemic risk. Objective To find a dose of intravitreous bevacizumab that was lower than previously used for severe ROP, was effective in this study, and could be tested in future larger studies. Design, Setting, and Participants Between May 2015 and September 2016, 61 premature infants with type 1 ROP in 1 or both eyes were enrolled in a masked, multicenter, phase 1 dose de-escalation study. One eye of 10 to 14 infants received 0.25 mg of intravitreous bevacizumab. If successful, the dose was reduced for the next group of infants (to 0.125 mg, then 0.063 mg, and finally 0.031 mg). Diluted bevacizumab was delivered using 300 µL syringes with 5/16-inch, 30-gauge fixed needles. Interventions Bevacizumab injections at 0.25 mg, 0.125 mg, 0.063 mg, and 0.031 mg. Main Outcomes and Measures Success was defined as improvement in preinjection plus disease or zone I stage 3 ROP by 5 days after injection or sooner, and no recurrence of type 1 ROP or severe neovascularization requiring additional treatment within 4 weeks. Results Fifty-eight of 61 enrolled infants had 4-week outcomes completed; mean birth weight was 709 g and mean gestational age was 24.9 weeks. Success was achieved in 11 of 11 eyes at 0.25 mg, 14 of 14 eyes at 0.125 mg, 21 of 24 eyes at 0.063 mg, and 9 of 9 eyes at 0.031 mg. Conclusions and Relevance A dose of bevacizumab as low as 0.031 mg was effective in 9 of 9 eyes in this phase 1 study and warrants further investigation. Identifying a lower effective dose of bevacizumab may reduce the risk for neurodevelopmental disability or detrimental effects on other organs.


Journal of Aapos | 2007

Comparison of the MTI Photoscreener and the Welch-Allyn SureSight autorefractor in a tertiary care center.

David L. Rogers; Daniel E. Neely; Janice Chapman; David A. Plager; Derek T. Sprunger; Naval Sondhi; Gavin J. Roberts; Susan Ofner

INTRODUCTION The MTI photoscreener (MTI) and the Welch-Allyn SureSight autorefractor are commonly used for preschool vision screening. We compared both of these methods on 100 consecutive patients in a prospective, randomized, masked, clinical trial conducted at a tertiary care center. METHODS One hundred patients between 1 and 6 years of age were included in the study. All participants underwent a comprehensive eye examination with cycloplegic refraction. Examination failure analysis was done on the SureSight data using the manufacturers referral criteria, the Vision in Preschoolers study (VIP) 90% specificity criteria, the VIP 94% specificity criteria, and the referral criteria proposed by Rowatt and colleagues. RESULTS Data were successfully obtained on 76% of children using the SureSight and 96% with the MTI. The sensitivity and specificity of the SureSight to detect clinically significant amblyogenic factors using the manufacturers criteria was 96.6 and 38.1%, using the VIP 90% criteria was 79.3 and 64.3%, using the VIP 94% criteria was 67.2 and 69.0%, and using criteria proposed by Rowatt and colleagues was 62.1 and 73.8%. The sensitivity and specificity of the MTI photoscreener was 94.8 and 88.1%, respectively. CONCLUSIONS Using the manufacturers referral criteria, the SureSight had a sensitivity equal to the MTI photoscreener; however, the specificity was low and over-referrals were anticipated. As specificity levels were increased, a substantial number of children with amblyogenic risk factors were not appropriately identified within our study population..


Journal of Child Neurology | 2015

Intracranial Hypertension Without Headache in Children

Shawn C. Aylward; Catherine Aronowitz; Rachel E. Reem; David L. Rogers; E. Steve Roach

We aimed to determine the frequency of intracranial hypertension without headache in children. We retrospectively analyzed patients evaluated in a pediatric intracranial hypertension referral center. Patients were divided into 2 groups depending on whether they complained of headache at the time of presentation. Age, body mass index, and opening cerebrospinal fluid pressures were considered continuous variables and compared by Wilcoxon rank-sum test because of non-normality. A P value of .05 was considered significant. A total of 228 charts were reviewed; 152 patients met the criteria for intracranial hypertension and 22/152 patients (14.5%) met the criteria of optic nerve edema without headache. There were clinically significant differences in age and body mass index between the 2 groups. The group without headache was typically younger and not obese. The opening pressure and modified opening pressure were not clinically significant between the 2 groups.


Journal of Aapos | 2012

Glaucoma in the Early Treatment for Retinopathy of Prematurity (ETROP) study

Don L. Bremer; David L. Rogers; William V. Good; Betty Tung; Robert J. Hardy; Rae R. Fellows

PURPOSE To report the clinical characteristics of infants with severe retinopathy of prematurity (ROP) and glaucoma-based on review of the Early Treatment for Retinopathy of Prematurity (ETROP) study. METHODS All infants randomized in the ETROP trial were included. Each infant developed high-risk prethreshold ROP in at least one eye. Infants were examined until 6 years postnatal age. The following data were collected: corneal clarity, depth of the anterior chamber, status of the optic nerve and cup/disk ratio, retinal structure, and visual acuity. The diagnosis of glaucoma was based on the investigators best clinical judgment. All infants diagnosed with glaucoma were included in the study. RESULTS A total of 12 of 718 eyes (1.67%) were diagnosed with glaucoma. Of these, 5 were first reported as having glaucoma at 9 months, 2 at 2 years, 1 each at 3 and 4 years, and 3 at 5 years. The anterior segment was shallow in 7 eyes. Three eyes had normal retinal structure, 1 had macular dragging, and 8 had retinal detachments involving the fovea (stage 4B or worse). At the 6-year follow-up examination only one eye with glaucoma had measurable vision. CONCLUSIONS Although earlier treatment of significant ROP has resulted in better retinal structure and visual acuity outcomes, nearly 2% of the eyes with high-risk prethreshold ROP developed glaucoma at some point during the first 6 years of life.


Archives of Ophthalmology | 2012

β-Blocking and Racial Variation in the Severity of Retinopathy of Prematurity

William V. Good; Robert J. Hardy; David K. Wallace; Don L. Bremer; David L. Rogers; R. Michael Siatkowski; Inge De Becker; C. Gail Summers; Rae R. Fellows; Betty Tung; Earl A. Palmer

AMD and this variant in other ethnic groups, and thus the possibility for systemic errors in other groups, remains largely unexplored. As our results highlight, predictive genetic testing for complex diseases faces many challenges. Until we fully understand how a particular genetic variant acts on disease susceptibility, great care must be taken when translating genetic tests from one race-ethnicity to another.

Collaboration


Dive into the David L. Rogers's collaboration.

Top Co-Authors

Avatar

Mary Lou McGregor

Nationwide Children's Hospital

View shared research outputs
Top Co-Authors

Avatar

Rachel E. Reem

Nationwide Children's Hospital

View shared research outputs
Top Co-Authors

Avatar

Don L. Bremer

Nationwide Children's Hospital

View shared research outputs
Top Co-Authors

Avatar

Shawn C. Aylward

Nationwide Children's Hospital

View shared research outputs
Top Co-Authors

Avatar

Rae R. Fellows

Nationwide Children's Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

William V. Good

Smith-Kettlewell Institute

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Raymond T. Kraker

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Richard P. Golden

Nationwide Children's Hospital

View shared research outputs
Researchain Logo
Decentralizing Knowledge